TOLMAR
TOLMAR is a privately held specialty pharmaceutical company that develops, manufactures, and commercializes long-acting injectables and oral products in urology, oncology, and endocrinology, serving patients with prostate cancer, central precocious puberty, hypogonadism, and mCRPC across 68-89 countries.
- Company typePrivate
- Founded2006
- HeadquartersFort Collins, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What TOLMAR does
TOLMAR is a privately held, fully integrated specialty pharmaceutical company founded in 2006 and headquartered in Fort Collins, Colorado, with U.S. sales and marketing operations based in Buffalo Grove, Illinois. The company develops, manufactures, and commercializes long-acting injectable and oral pharmaceutical products across three therapeutic areas: urology (ELIGARD for advanced prostate cancer, JATENZO for testosterone replacement in hypogonadism), endocrinology (FENSOLVI for central precocious puberty in pediatric patients), and oncology (Rubraca, a PARP inhibitor for metastatic castration-resistant prostate cancer). End customers are healthcare providers — urologists, oncologists, endocrinologists, and advanced practice providers — and the patients they treat in these specialty niches.
The company's core technical asset is the proprietary ATRIGEL Delivery System, a controlled-release polymeric gel technology that enables subcutaneous long-acting injectable formulations of leuprolide acetate with programmable release profiles across 1-, 3-, 4-, and 6-month dosing intervals. Manufacturing is anchored in Colorado: roughly 110,000 square feet of R&D and production in Fort Collins, a 225,000-square-foot drug distribution and manufacturing site in Windsor (NABP-accredited), and a newer Northern Illinois Laboratory at Rosalind Franklin University in North Chicago for pharmaceutical development. Across the portfolio the company cites 38 approved products, 17M+ units produced since 2002, and distribution in 68-89 countries.
TOLMAR's commercial model combines a U.S. specialty sales force targeting urology, oncology, and hospital channels with global out-licensing to regional pharmaceutical partners for international distribution. The company supplements its proprietary portfolio with strategic in-licensing and promotional agreements (e.g., the pharma& Group for Rubraca), an exclusive telemedicine partnership with UpScriptHealth to broaden access to oral testosterone replacement, and a Patient Assistance Program covering copay support, benefit verification, and financial assistance. Revenue is generated from prescription product sales in the U.S. and from licensing/royalty income on products distributed internationally by partners.
TOLMAR firmographics
Firmographics- Name
- TOLMAR
- Legal name
- Tolmar Holdings, Inc.
- Website
- https://tolmar.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- TOLMAR is a privately held specialty pharmaceutical company that develops, manufactures, and commercializes long-acting injectables and oral products in urology, oncology, and endocrinology, serving patients with prostate cancer, central precocious puberty, hypogonadism, and mCRPC across 68-89 countries.
- Ownership category
- akta.pro rank
TOLMAR industry classification
Industry- Product category
- Specialty Pharmaceuticals
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
- akta.pro secondary industry
- Genitourinary Oncology (HLAKAFAM)
Keywords
Where TOLMAR is headquartered
LocationHeadquarters
- HQ city
- Fort Collins
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
TOLMAR business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Specialty Pharmaceutical Products: Revenue generated from sale of proprietary specialty pharmaceutical products including ELIGARD for prostate cancer, FENSOLVI for central precocious puberty, and JATENZO for testosterone replacement therapy. Products are prescription-based and distributed through pharmacy channels.
- Licensing and Manufacturing Services: Tolmar serves as innovator, developer, and global manufacturer for pharmaceutical products distributed worldwide through licensing partnerships. ELIGARD is marketed in 68-89 countries by Tolmar and its partners.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | Prescription pharmaceutical products - pricing determined by market and insurance coverage |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
TOLMAR product offering
Product offeringCore offering
Tolmar is a fully integrated specialty pharmaceutical company that develops, manufactures, and commercializes proprietary long-acting injectables and oral pharmaceutical products. Its core offerings include ELIGARD (leuprolide acetate injectable suspension) for advanced prostate cancer, FENSOLVI (leuprolide acetate) for central precocious puberty, JATENZO (testosterone undecanoate oral softgel) for hypogonadism, and promotional rights to Rubraca (rucaparib) for metastatic castration-resistant prostate cancer, all built around its proprietary ATRIGEL controlled-release delivery technology.
Product overview
Tolmar is a fully integrated specialty pharmaceutical company that develops, manufactures, and commercializes long-acting injectable and oral pharmaceutical products. The core product portfolio centers on three key therapeutic areas: urology (Eligard for prostate cancer, Jatenzo for testosterone replacement), oncology (Rubraca PARP inhibitor), and endocrinology (Fensolvi for central precocious puberty). The company operates with proprietary delivery technologies including the ATRIGEL Delivery System for injectable suspensions and commercializes its products directly and through strategic partnerships across global markets.
Differentiator
Problem solved
Functional benefit
Brands
- Fensolvi: First and only 6-month subcutaneous injection for Central Precocious Puberty (CPP), a GnRH agonist therapy for children with CPP.
- Eligard
- Jatenzo
Products and services
- ELIGARD (leuprolide acetate for injectable suspension) A gonadotropin releasing hormone (GnRH) agonist for the palliative treatment of advanced prostate cancer, delivered via the proprietary ATRIGEL Delivery System as a long-acting subcutaneous injection available in 1-, 3-, 4-, and 6-month dosing formulations. Indicated for advanced prostate cancer patients requiring androgen deprivation therapy.
- FENSOLVI (leuprolide acetate for injectable suspension) The first and only 6-month subcutaneous GnRH agonist injection for central precocious puberty (CPP) in children, designed to delay puberty with twice-yearly dosing. Indicated for pediatric patients with CPP requiring gonadotropin releasing hormone therapy.
- JATENZO (testosterone undecanoate) An FDA-approved oral softgel testosterone replacement therapy (testosterone undecanoate) for men with low or no testosterone due to hypogonadism. The first oral softgel testosterone product approved in the U.S. in over 60 years; acquired by Tolmar in October 2022.
- Rubraca (rucaparib) A PARP inhibitor promoted by Tolmar in the U.S. under an exclusive promotional agreement with the pharma& Group, with expanded FDA approval for use before chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) patients who have received prior androgen-directed therapy. Indicated for mCRPC based on the TRITON3 Phase 3 trial showing superiority over docetaxel.
Quantifiable outcome
- 88% of patients reached nadir testosterone ≤5 ng/dL with median nadir T of 3.5 ng/dL in ELIGARD clinical trials
- +3 more outcomes
Companies that use TOLMAR
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
TOLMAR technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
TOLMAR partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Alpha Tau MedicalcoreStrategic collaboration to bring Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) to U.S. urological cancer patients. Alpha Tau Medical pioneered Alpha DaRT technology for localized alpha particle radiation treatment of solid tumors.
- Rosalind Franklin UniversitycoreTolmar opened Northern Illinois Laboratory at Rosalind Franklin University's Innovation and Research Park in North Chicago. The facility expands pharmaceutical development capacity and fosters biomedical innovation collaborations.
- UpScriptHealthcoreCollaboration with direct-to-patient telemedicine company to increase access to oral testosterone replacement therapy. UpScriptHealth provides virtual consultation and prescription services for TRT.
- the pharma& GroupcoreExclusive promotional agreement for Rubraca (rucaparib) in the U.S. for treatment of metastatic castration-resistant prostate cancer. Pharma& Group promotes the PARP inhibitor to healthcare providers.
- Global Pharmaceutical Distribution PartnerscoreProducts marketed in 68-89 countries worldwide through licensing partnerships with regional pharmaceutical distributors and marketing partners.
Scale indicators7 records
Recent moves6 records
Expansion highlights7 records
TOLMAR competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
TOLMAR social profiles
Digital presenceTOLMAR compliance and trust
Trust signalCompliance4 records
TOLMAR financial estimates
Financial estimateRevenue estimate
Valuation estimate
TOLMAR leadership team
Management profileNumber of profiles
Profiles8 records
TOLMAR subsidiaries and ownership
Company hierarchySubsidiaries3 records
TOLMAR funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TOLMAR M&A and investment
M&A and investmentM&A2 records
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TOLMAR
What does TOLMAR do?
Tolmar is a fully integrated specialty pharmaceutical company that develops, manufactures, and commercializes proprietary long-acting injectables and oral pharmaceutical products. Its core offerings include ELIGARD (leuprolide acetate injectable suspension) for advanced prostate cancer, FENSOLVI (leuprolide acetate) for central precocious puberty, JATENZO (testosterone undecanoate oral softgel) for hypogonadism, and promotional rights to Rubraca (rucaparib) for metastatic castration-resistant prostate cancer, all built around its proprietary ATRIGEL controlled-release delivery technology.
Is TOLMAR a public or private company?
TOLMAR is a private company. It is classified as unknown and is currently operating.
When was TOLMAR founded?
TOLMAR was founded in 2006. It employs 501 to 1,000 people.
Where is TOLMAR based?
TOLMAR is headquartered in Fort Collins, United States, in the North America region.
How does TOLMAR make money?
Two revenue lines are on record. Specialty Pharmaceutical Products are the primary driver. The others are licensing and Manufacturing Services.
Does TOLMAR have an API?
No public API is recorded for TOLMAR.
What industry is TOLMAR in?
TOLMAR's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals, with a secondary code of HLAKAFAM, Genitourinary Oncology. Its SIC code is 2834.